title: Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial.
authors.forename: G
authors.initials: G
authors.lastname: Jäger
authors.forename: P
authors.initials: P
authors.lastname: Neumeister
authors.forename: F
authors.initials: F
authors.lastname: Quehenberger
authors.forename: S
authors.initials: S
authors.lastname: Wöhrer
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: M
authors.initials: M
authors.lastname: Raderer
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D012074:Remission Induction; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine